Eric Jonasch, MD is Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Center at the University of Texas M. D. Anderson Cancer Center in Houston, Texas. He held his clinical residency in internal medicine at the Royal Victoria Hospital in Montreal, Canada, his clinical fellowship in hematology/oncology at the New England Medical Center in Boston, Massachusetts, and his research fellowship at the Beth Israel Deaconess Medical Center in Boston, Massachusetts. He was on faculty at the Massachusetts General Hospital for three years before moving to MD Anderson Cancer Center in Houston.

Dr. Jonasch is director of the VHL Clinical Center at the MD Anderson Cancer Center, and is involved in tissue-based translational research in renal cell carcinoma and VHL disease. He heads a number of investigator-initiated clinical trials, and is PI of the Department of Defense Kidney Cancer Research Consortium and VHL Research Consortium Dr. Jonasch is in charge on an ongoing laboratory research effort evaluating the determinants of response and resistance to therapy in renal cell carcinoma and VHL disease. Dr. Jonasch’s current work focuses on understanding the drivers of renal cell carcinoma tumor ontogeny, and the development of informative models of tumor-microenvironmental interaction.

Dr. Jonasch serves as Vice-Chair of the NCCN Kidney Cancer Guideline Panel, and is a Board member of the International Kidney Cancer Coalition.